There are several biomarkers to identify patients who may benefit from immunotherapies, including the PD-L1 status of tumor cells (and immune cells in the tumor microenvironment), tumor mutation burden, invasion of CD8-positive cells, and the absence of suppressive immune cells. The gene discussed is CD8A; the disease is neoplasm.